Lisa Rodríguez

1.7k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

Lisa Rodríguez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Lisa Rodríguez has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Hepatology. Recurrent topics in Lisa Rodríguez's work include Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Lisa Rodríguez is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Lisa Rodríguez collaborates with scholars based in United States, Germany and Colombia. Lisa Rodríguez's co-authors include Richard Pazdur, Martha Donoghue, Marc R. Theoret, Steven J. Lemery, Reena Philip, Lola A. Fashoyin‐Aje, Julia A. Beaver, Kirsten B. Goldberg, Mengdie Yuan and Leigh Marcus and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and The Oncologist.

In The Last Decade

Lisa Rodríguez

19 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

2021 330 citations Leigh Marcus, Lola A. Fashoyin‐Aje et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Lisa Rodríguez

Since Specialization

Citations

This map shows the geographic impact of Lisa Rodríguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Rodríguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Rodríguez more than expected).

Fields of papers citing papers by Lisa Rodríguez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Rodríguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Rodríguez. The network helps show where Lisa Rodríguez may publish in the future.

Co-authorship network of co-authors of Lisa Rodríguez

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Rodríguez. A scholar is included among the top collaborators of Lisa Rodríguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Rodríguez. Lisa Rodríguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Key Opinion Leaders’ Interviews to Inform the Future of Benefit–Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations 2024 ·Drug Safety ·Arianna Simonetti, Susan Colilla, Brian Edwards, (unknown), Leila G. Lackey, Lisa Rodríguez, Susan Talbot, Hong Yang, William Yang Wang, (unknown), (unknown)	1
2	A Survey to Assess the Current Status of Structured Benefit-Risk Assessment in the Global Drug and Medical Device Industry 2024 ·Therapeutic Innovation & Regulatory Science ·Martin Gebel, Cheryl Renz, Lisa Rodríguez, Arianna Simonetti, Hong Yang, Brian Edwards, (unknown), (unknown), Michael W. Colopy	3
3	Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions 2022 ·Pharmaceutical Medicine ·(unknown), Lisa Rodríguez, Andreas Brueckner, Kerry Jo Lee, (unknown), (unknown), (unknown), Shuai Yuan	1
4	FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial 2022 ·The Oncologist ·Dianne Pulte, Haiyan Chen, Lauren Price, Ramadevi Gudi, Hongshan Li, Ólanrewaju O. Okusanya, Lian Ma, Lisa Rodríguez, Jonathon Vallejo, Kelly J. Norsworthy, R. Angelo de Claro, Marc R. Theoret, Richard Pazdur	32
5	FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib 2021 ·The Oncologist ·May Tun Saung, Lorraine Pelosof, Sandra J. Casak, Martha Donoghue, Steven J. Lemery, Mengdie Yuan, Lisa Rodríguez, (unknown), Meredith K. Chuk, (unknown), Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Lola A. Fashoyin‐Aje	77
6	FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer 2021 ·The Oncologist ·Luckson Mathieu, Sujay Shah, Lee H. Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodríguez, Pallavi S. Mishra‐Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh	102
7	FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors breakdown → 2021 ·Clinical Cancer Research ·Leigh Marcus, Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher, Reena Philip, Soma Ghosh, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Steven J. Lemery	330
8	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review 2021 ·Clinical Cancer Research ·Paz J. Vellanki, Flora Mulkey, (unknown), Lisa Rodríguez, Yibo Wang, Yuan Xu, Hong Zhao, Jiang Liu, (unknown), (unknown), Qiuyi Choo, (unknown), (unknown), Kwadwo Ameyaw Korsah, Dianne Spillman, R. Angelo de Claro, Richard Pazdur, Julia A. Beaver, Harpreet Singh	41
9	FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma 2020 ·The Oncologist ·Abhilasha Nair, Kelie Reece, Martha Donoghue, Weishi Yuan, Lisa Rodríguez, Patricia Keegan, Richard Pazdur	61
10	FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma 2020 ·Clinical Cancer Research ·Sandra J. Casak, Martha Donoghue, Lola A. Fashoyin‐Aje, Xiaoping Jiang, Lisa Rodríguez, Yuan Li Shen, Yuan Xu, Xiling Jiang, Jiang Liu, Hong Zhao, William F. Pierce, (unknown), Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Richard Pazdur, Steven J. Lemery	130
11	An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report 2019 ·Journal of Medical Case Reports ·(unknown), (unknown), (unknown), Lisa Rodríguez, Luz F. Sua, Ángela R. Zambrano	0
12	FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations 2018 ·The Oncologist ·Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal, Erin Larkins, Kirsten B. Goldberg, (unknown), Karen E. Bijwaard, Eunice Lee, Reena Philip, Xiaoping Jiang, Lisa Rodríguez, Amy E. McKee, Patricia Keegan, Richard Pazdur	166
13	Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib 2018 ·The Oncologist ·Lorraine Pelosof, Steven J. Lemery, Sandra J. Casak, Xiaoping Jiang, Lisa Rodríguez, (unknown), Youwei Bi, Jiang Liu, Jeanne Fourie Zirkelbach, (unknown), Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur	15
14	FDA's Approval of the First Biosimilar to Bevacizumab 2018 ·Clinical Cancer Research ·Sandra J. Casak, Steven J. Lemery, Jee Young Chung, (unknown), Sarah J. Schrieber, Edwin C.Y. Chow, Weishi Yuan, Lisa Rodríguez, Thomas Gwise, Anne Rowzee, (unknown), Patricia Keegan, Amy E. McKee, Richard Pazdur	28
15	FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation 2017 ·The Oncologist ·Lauretta Odogwu, Luckson Mathieu, Kirsten B. Goldberg, Gideon M. Blumenthal, Erin Larkins, Mallorie H. Fiero, Lisa Rodríguez, Karen E. Bijwaard, Eunice Y. Lee, Reena Philip, (unknown), Martha Donoghue, Patricia Keegan, Amy S. McKee, Richard Pazdur	49
16	Mutación BRAF V600E en pacientes con cáncer de tiroides. Fundación Clínica Valle del Lili: una serie de casos 2017 ·SHILAP Revista de lepidopterología ·Guillermo Guzmán, (unknown), (unknown), Juliana Escobar, Lisa Rodríguez, (unknown)	1
17	Neuromyelitis Optica in Child: Diagnostic and Therapeutic Challenges 2013 ·SHILAP Revista de lepidopterología ·(unknown), Maria Gieron‐Korthals, Carlos R. Martinez, Lisa Rodríguez	6
18	Criminal Justice Realignment: A Prosecutor’s Perspective 2013 ·Federal Sentencing Reporter ·Lisa Rodríguez	1
19	Three Distinct Cases of Copper Deficiency in Hospitalized Pediatric Patients 2012 ·Clinical Pediatrics ·(unknown), (unknown), (unknown), Lisa Rodríguez	11
20	THE YOUNG CHILD'S MEMORY FOR WORDS: Developing First and Second Language Literacy 2004 ·Lisa Rodríguez	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact